Brought to you by 
Series C round brings $52mm to Deciphera
26 Sep 2017
Executive Summary
Deciphera Pharmaceuticals LLC (small-molecule cancer therapies) raised $52mm in its Series C round to lead investors Redmile Group, Viking Global Investors, and Sphera Global Healthcare Fund, which were joined by existing investors including New Leaf Venture Partners. Funds will support ongoing development of DCC2618 (in Phase I for gastrointestinal stromal tumors, aggressive systemic mastocytosis, and malignant gliomas) and DCC3014 (Phase I for advanced malignancies). Deciphera last raised funds through a Series B round that began at $75mm in 2015 and closed at over $90mm last year.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C round brings $52mm to Deciphera
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice